查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594695

口服蛋白质和胜肽市场：按药物类型、应用分类 - 全球预测 2025-2030

Oral Proteins & Peptides Market by Drug Type (Calcitonin, Insulin, Linaclotide), Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年口服蛋白和胜肽市值为14亿美元，预计2024年将达到15.9亿美元，复合年增长率为13.37%，预计2030年将达到33.8亿美元。

口服蛋白质和胜肽市场包括透过口服途径提供的基于蛋白质和胜胜肽的疗法的开发和商业化。这个市场是由解决糖尿病、癌症和骨质疏鬆症等慢性疾病的需求所驱动的，口服给药可以显着提高患者的依从性和治疗效果。应用范围包括药物治疗，透过药物传输技术的进步，传统上透过注射给药的胜胜肽已被修改为口服摄取。最终使用目标主要是製药公司、生物技术公司、研究机构和受託研究机构，旨在扩大对口服生技药品的需求。

主要市场统计
基准年[2023] 14亿美元
预测年份 [2024] 15.9亿美元
预测年份 [2030] 33.8亿美元
复合年增长率（%） 13.37%

该市场的关键成长要素包括奈米技术和口服药物传输系统的进步，这可以生物有效性蛋白质和胜肽的生物利用度和稳定性。需要长期治疗方法的慢性病的盛行率日益增加，这是市场扩张的重大机会。此外，值得注意的是，大型製药企业越来越多地投资于研发（R&D），以将新的口服生技药品推向市场。为了充分利用这些机会，公司应该投资于联合研发伙伴关係和合作。

然而，市场成长受到限制，例如由于胃肠道降解和吸收率变化而导致实现高生物有效性的固有挑战。此外，与生物治疗药物核准相关的监管复杂性也可能阻碍进展。为了克服这些障碍，该产业可以专注于创新领域，例如设计更稳定的蛋白质结构、利用蛋白酶抑制剂以及开发新型赋形剂和配方技术。

该市场表现出进步的性质，具有颠覆性创新的巨大潜力，可以增强以患者为中心的解决方案。我们的结果表明，对个人化医疗日益增长的兴趣正在推动研究和开发，以创造更有针对性和更有效的口服胜胜肽疗法。企业应专注于优化口服给药流程，开拓开拓的市场，以建立竞争优势并有效发展业务。

市场动态：揭示快速发展的口服蛋白质和胜胜肽市场的关键市场洞察

供需的动态交互作用正在改变口服蛋白质和胜胜肽市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 慢性病增加
    • 增加患者对口服药物的偏好
    • 口服蛋白质和胜肽所需的材料充足
  • 市场限制因素
    • 口服胜胜肽生产成本高
  • 市场机会
    • 用于口服递送的奈米粒子的出现
    • 製药公司加强研发力度
  • 市场挑战
    • 对不必要的酵素降解和固有结构复杂性的担忧

波特的五力：驾驭口服蛋白质和胜肽市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解口服蛋白质和胜肽市场的外部影响

外部宏观环境因素在塑造口服蛋白质和胜肽市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解口服蛋白质和胜肽市场的竞争格局

口服蛋白质和胜肽市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位基质口服蛋白胜胜肽市场供应商绩效评估

FPNV定位矩阵是评估口服蛋白和胜肽市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，规划口服蛋白质和胜肽市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，口服蛋白质和胜肽市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病盛行率增加
      • 更多患者喜欢口服药物
      • 适合口服蛋白质和胜肽的材料充足
    • 抑制因素
      • 口服胜胜肽生产成本高
    • 机会
      • 口服奈米颗粒的出现
      • 製药公司加强研发力度
    • 任务
      • 对不必要的酵素降解和固有结构复杂性的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 口服蛋白/胜胜肽市场药物（依类型）

  • 抑钙素
  • 胰岛素
  • Linaclotide
  • Octreotide
  • Plecanatide

第七章口服蛋白/胜胜肽市场：依应用分类

  • 骨病
  • 糖尿病
  • 胃和消化系统疾病
  • 荷尔蒙失调

第八章美洲口服蛋白和胜胜肽市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太口服蛋白胜胜肽市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲口服蛋白胜胜肽市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Almac Group
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Catalent, Inc.
  • Chiasma, Inc.
  • Eli Lilly and Company
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer, Inc.
  • Proxima Concepts Limited
  • Sanofi SA
Product Code: MRR-036C5CF3B4AA

The Oral Proteins & Peptides Market was valued at USD 1.40 billion in 2023, expected to reach USD 1.59 billion in 2024, and is projected to grow at a CAGR of 13.37%, to USD 3.38 billion by 2030.

The oral proteins and peptides market encompasses the development and commercialization of protein and peptide-based therapeutics delivered via the oral route. This market is driven by the necessity to address chronic diseases such as diabetes, cancer, and osteoporosis, where oral delivery can significantly enhance patient compliance and therapeutic effectiveness. The application scope includes pharmacological treatments where peptides, traditionally administered through injections, are reformulated for oral ingestion thanks to advancements in drug delivery technologies. The end-use spectrum predominantly targets pharmaceutical and biotechnology companies, research institutes, and contract research organizations, aiming to tap into the growing demand for orally administered biologics.

KEY MARKET STATISTICS
Base Year [2023] USD 1.40 billion
Estimated Year [2024] USD 1.59 billion
Forecast Year [2030] USD 3.38 billion
CAGR (%) 13.37%

Critical growth factors in this market include advancements in nanotechnology and oral drug delivery systems, enabling better bioavailability and stability of proteins and peptides. The increasing prevalence of chronic diseases requiring long-term treatment regimens presents substantial opportunities for market expansion. Additionally, increasing investments in research and development (R&D) by major pharmaceutical companies to bring novel oral biologics to market are noteworthy. Companies should invest in partnerships and collaborations for co-research and development to maximize these opportunities.

However, market growth is restricted by limitations such as the inherent challenges in achieving high oral bioavailability due to degradation in the gastrointestinal tract and variable absorption. Furthermore, regulatory complexities associated with the approval of biotherapeutics may also impede progress. To overcome these hurdles, the industry can focus on innovative areas such as designing more stable protein structures, utilizing protease inhibitors, and developing novel excipients and formulation technologies.

The market exhibits a progressive nature, with significant potential for disruptive innovations that enhance patient-centric solutions. Insights suggest a growing interest in personalized medicine, which is driving R&D towards creating more targeted and effective oral peptide therapies. Businesses should focus on optimizing the oral delivery process and exploring untapped markets to establish a competitive edge and foster business growth effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oral Proteins & Peptides Market

The Oral Proteins & Peptides Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in prevalence of chronic diseases
    • Rise in patient preference for oral drugs
    • Adequate availability of materials for oral delivery of proteins and peptides
  • Market Restraints
    • High manufacturing costs of oral peptides
  • Market Opportunities
    • Emergence of nanoparticles for oral delivery
    • Increase in R&D by pharmaceutical companies
  • Market Challenges
    • Concerns related to unwanted enzymatic degradation and inherent structural complexities

Porter's Five Forces: A Strategic Tool for Navigating the Oral Proteins & Peptides Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oral Proteins & Peptides Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oral Proteins & Peptides Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oral Proteins & Peptides Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oral Proteins & Peptides Market

A detailed market share analysis in the Oral Proteins & Peptides Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oral Proteins & Peptides Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oral Proteins & Peptides Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oral Proteins & Peptides Market

A strategic analysis of the Oral Proteins & Peptides Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oral Proteins & Peptides Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Almac Group, Astellas Pharma Inc., AstraZeneca PLC, Biocon Limited, Catalent, Inc., Chiasma, Inc., Eli Lilly and Company, Merck KGaA, Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer, Inc., Proxima Concepts Limited, and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Oral Proteins & Peptides Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Calcitonin, Insulin, Linaclotide, Octreotide, and Plecanatide.
  • Based on Application, market is studied across Bone Diseases, Diabetes, Gastric & Digestive Disorders, and Hormonal Disorders.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in prevalence of chronic diseases
      • 5.1.1.2. Rise in patient preference for oral drugs
      • 5.1.1.3. Adequate availability of materials for oral delivery of proteins and peptides
    • 5.1.2. Restraints
      • 5.1.2.1. High manufacturing costs of oral peptides
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of nanoparticles for oral delivery
      • 5.1.3.2. Increase in R&D by pharmaceutical companies
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns related to unwanted enzymatic degradation and inherent structural complexities
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Oral Proteins & Peptides Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Calcitonin
  • 6.3. Insulin
  • 6.4. Linaclotide
  • 6.5. Octreotide
  • 6.6. Plecanatide

7. Oral Proteins & Peptides Market, by Application

  • 7.1. Introduction
  • 7.2. Bone Diseases
  • 7.3. Diabetes
  • 7.4. Gastric & Digestive Disorders
  • 7.5. Hormonal Disorders

8. Americas Oral Proteins & Peptides Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Oral Proteins & Peptides Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Oral Proteins & Peptides Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Almac Group
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Biocon Limited
  • 6. Catalent, Inc.
  • 7. Chiasma, Inc.
  • 8. Eli Lilly and Company
  • 9. Merck KGaA
  • 10. Novartis AG
  • 11. Novo Nordisk A/S
  • 12. Oramed Pharmaceuticals Inc.
  • 13. Pfizer, Inc.
  • 14. Proxima Concepts Limited
  • 15. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. ORAL PROTEINS & PEPTIDES MARKET RESEARCH PROCESS
  • FIGURE 2. ORAL PROTEINS & PEPTIDES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ORAL PROTEINS & PEPTIDES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ORAL PROTEINS & PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ORAL PROTEINS & PEPTIDES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ORAL PROTEINS & PEPTIDES MARKET DYNAMICS
  • TABLE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LINACLOTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PLECANATIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY BONE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GASTRIC & DIGESTIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ORAL PROTEINS & PEPTIDES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 105. ORAL PROTEINS & PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2023